Table 2. Top 40 survival mechanisms found by SURCOMED in 1,791 breast cancer patients.
| Biological processes, molecular mechanisms and pathways | Occurrences | State |
|---|---|---|
| Reactome nuclear signaling by ERBB4 | 35 | Up |
| Amine binding | 31 | Up |
| Auxiliary transport protein activity | 31 | Up |
| Neuron differentiation | 31 | Up |
| Transmembrane receptor protein serine threonine kinase signaling pathway | 31 | Up |
| Axonogenesis | 30 | Up |
| PID ERA genomic pathway | 30 | Up |
| PID HNF3A pathway | 30 | Up |
| Reactome G alpha S signaling events | 30 | Up |
| Ligand dependent nuclear receptor activity | 29 | Up |
| Neurite development | 29 | Up |
| Reactome phase1 functionalization of compounds | 29 | Up |
| Cellular morphogenesis during differentiation | 27 | Up |
| Channel regulator activity | 27 | Up |
| Kegg drug metabolism cytochrome P450 | 27 | Up |
| Pattern specification process | 27 | Up |
| Biocarta BAD pathway | 26 | Up |
| Neurogenesis | 26 | Up |
| Reactome nuclear receptor transcription pathway | 26 | Up |
| Transforming growth factor beta receptor signaling pathway | 25 | Up |
| Reactome kinesins | 44 | Down |
| Regulation of mitosis | 44 | Down |
| M phase | 43 | Down |
| Reactome cell cycle checkpoints | 43 | Down |
| Transferase activity transferring phosphorus containing groups | 43 | Down |
| M phase of mitotic cell cycle | 42 | Down |
| Mitosis | 42 | Down |
| Organelle organization and biogenesis | 42 | Down |
| Reactome assembly of the pre replicative complex | 42 | Down |
| Reactome cell cycle | 42 | Down |
| Reactome DNA replication | 42 | Down |
| Reactome M-G1 transition | 42 | Down |
| Reactome mitotic M–M–G1 phases | 42 | Down |
| Reactome regulation of mitotic cell cycle | 42 | Down |
| Cell cycle process | 41 | Down |
| Chromosome segregation | 41 | Down |
| PID ATR pathway | 41 | Down |
| Reactome APC C CDH1 mediated degradation of CDC20 and other APC C CDH1 targeted proteins in late mitosis early G1 | 41 | Down |
| Reactome cell cycle mitotic | 41 | Down |
| Cell cycle GO 0007049 | 40 | Down |
The table shows the most frequent up- and downregulated biological mechanisms across the top 50 combinations of survival markers. Highlighted in italic, 'ATR pathway', 'Nuclear signaling by ERBB4' (HER4), 'HNF3A (FOXA1) pathway', and 'Transforming growth factor beta (TGFB) signaling pathway', appeared in 82, 70, 60 and 50% of the survival combinations of markers, respectively. They constitute examples of well-known cancer-driving mechanisms.